Introduction: Biochemical diagnosis of endogenous hyperinsulinemic hypoglycemia is straightforward. Surgical removal of an insulinoma is hampered by difficulties to localize it using conventional radiological procedures. In vitro data suggest that human insulinoma cells exhibit a high density of GLP-1R. 111In-exendin-4 is an 111In labeled GLP-1R agonist that binds with high affinity to GLP-1R and may be helpful in localizing insulinomas.
Aim(s): To localize benign insulinomas using 111In-exendin-4 in patients with proven endogenous hyperinsulinemic hypoglycemia but no or one suspicious lesion on conventional imaging.
Materials and methods: 111In-exendin-4 was administered intravenously at a dose of (˜90 MBq) over five minutes to 30 patients (18 females, 12 males, age 53.5±14.9 years, mean±SD). Whole body planar images and SPECT/CT images of the abdomen were performed at 0.5h, 4h, 23h, 96h up to 168h post injection. Diagnosis was confirmed by histology after surgery.
Conference: 9th Annual ENETS Conference (2012)
Presenting Author: MD, PhD Emanuel Christ
To read results and conclusion, please login ...
Further abstracts you may be interested in